Drug Development

Voyager Therapeutics' new gene therapy just cleared a key FDA hurdle. With promising preclinical data, it's a major momentum signal in the fight against Alzheimer's.

After an initial rejection, Sydnexis's pediatric myopia drug gets a crucial FDA hearing, raising hopes for the first approved U.S. pharmaceutical treatment.

By hiring top drug and deal makers, Bexorg signals its AI-powered human brain platform is ready to move from a bold experiment to a commercial powerhouse.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

A mining firm just secured a key gene therapy patent for ALS. Timothy Bell dissects the audacious strategy of funding cutting-edge biotech with Greenland's mineral wealth.

The Novo Nordisk Foundation's record €80M grant program isn't just charity. It's a calculated move to reshape European science and tackle crises from soil health to obesity.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

Rani Therapeutics partners with PegBio, betting its drug-injecting capsule can unlock novel oral obesity therapies and challenge market giants.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Amplia Therapeutics' new patent application for novel FAK inhibitors extends protection to 2046, signaling a major play in oncology and fibrosis markets.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.

An AI infrastructure firm just used its own tech to design safer painkillers, tackling the liver toxicity risks of common drugs. What does this mean for pharma?

A biotech firm just printed kidney and liver tissue in space for the first time, proving orbital manufacturing isn't science fiction, but our medical future.

As Immunic executives meet investors, the real audience is the future. With pivotal data on its MS drug due this year, the firm is navigating a high-risk path.